Chong Kun Dang embarked on the patent challenge of Celebrex
Chong Kun Dang embarked on the patent challenge of Celebrex (Pfizer Korea) which is an absolute leader in the field analgesic and anti-inflammatory.
Celebrex is one of the cox-2 inhibitors for pain relief recording sales of 50 billion won annually, and its patent expires system on June 11 next y...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
